Physician profile
Daniel P Feldman
NPI 1467471193
$18,068.00
in general payments reported to CMS, 2019-2025
48 companies · $5,547 in 2025
The $5,547 reported for 2025 was more than what 94% of Pain Medicine (Anesthesiology) providers received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,309 · 2020: $1,120 · 2021: $1,286 · 2022: $1,697 · 2023: $2,199 · 2024: $4,909 · 2025: $5,547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,406 · Consulting Fee: $2,500 · Travel and Lodging: $1,749.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,406.26 |
| Consulting Fee | $2,500.00 |
| Travel and Lodging | $1,748.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Saluda Medical Americas, INC. | $6,864.17 | 2023-2025 | Evoke, Evoke Scs |
| Abbvie INC. | $2,231.06 | 2021-2025 | |
| Abbott Laboratories | $2,008.68 | 2019-2025 | Eterna, Proclaim, Octrode |
| Medtronic, INC. | $1,195.77 | 2021-2025 | Intellis Adaptivestim, Osteocool Rf Ablation System, Kyphon Express II Kyphopak Tray |
| Amgen INC. | $710.70 | 2020-2022 | |
| Zyla Life Sciences, INC. | $591.40 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $434.14 | 2020-2025 | Belbuca |
| Pfizer INC. | $396.80 | 2019-2025 | |
| Scilex Pharmaceuticals INC. | $319.19 | 2019-2025 | Ztlido |
| Upsher-Smith Laboratories LLC | $289.92 | 2020-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $271.10 | 2022 | |
| Medtronic USA, INC. | $206.98 | 2019 | |
| Vertos Medical, INC. | $204.75 | 2023-2024 | Mild Device Kit |
| Lundbeck LLC | $204.15 | 2023-2025 | Vyepti |
| Averitas Pharma INC. | $201.83 | 2024-2025 | Qutenza |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Feldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.